EA201490175A1 - Составы дезоксихолевой кислоты и ее солей - Google Patents

Составы дезоксихолевой кислоты и ее солей

Info

Publication number
EA201490175A1
EA201490175A1 EA201490175A EA201490175A EA201490175A1 EA 201490175 A1 EA201490175 A1 EA 201490175A1 EA 201490175 A EA201490175 A EA 201490175A EA 201490175 A EA201490175 A EA 201490175A EA 201490175 A1 EA201490175 A1 EA 201490175A1
Authority
EA
Eurasian Patent Office
Prior art keywords
deoxic
salts
compositions
acid
level
Prior art date
Application number
EA201490175A
Other languages
English (en)
Other versions
EA029305B1 (ru
Inventor
Роберт Эмил Ходж
Джеффри Дуглас Вебстер
Роберт М. Мориарти
Original Assignee
Китера Биофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45569726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490175(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Китера Биофармасьютикалз, Инк. filed Critical Китера Биофармасьютикалз, Инк.
Publication of EA201490175A1 publication Critical patent/EA201490175A1/ru
Publication of EA029305B1 publication Critical patent/EA029305B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящая заявка относится к водной фармацевтической композиции, содержащей от приблизительно 0,4% (мас./об.) до менее чем приблизительно 2% (мас./об.) соли дезоксихолевой кислоты, причем рН указанной композиции сохраняется на уровне от приблизительно 8,1 до приблизительно 8,5, что обеспечивает указанной композиции устойчивость к выпадению в осадок. Также в настоящей заявке предложены способы стабилизации водной фармацевтической композиции, содержащей от приблизительно 0,4% (мас./об.) до менее чем приблизительно 2% (мас./об.) соли дезоксихолевой кислоты, для предотвращения образования осадка, при этом указанный способ включает поддержание рН указанного раствора на уровне от приблизительно 8,1 до приблизительно 8,5.
EA201490175A 2011-08-23 2011-08-23 Составы дезоксихолевой кислоты и ее солей EA029305B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/048806 WO2013028177A1 (en) 2011-08-23 2011-08-23 Formulations of deoxycholic acid and salts thereof

Publications (2)

Publication Number Publication Date
EA201490175A1 true EA201490175A1 (ru) 2014-06-30
EA029305B1 EA029305B1 (ru) 2018-03-30

Family

ID=45569726

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490175A EA029305B1 (ru) 2011-08-23 2011-08-23 Составы дезоксихолевой кислоты и ее солей

Country Status (18)

Country Link
JP (1) JP5919597B2 (ru)
KR (5) KR20200013103A (ru)
CN (3) CN103826608A (ru)
AU (3) AU2011375432B2 (ru)
BR (1) BR112014000547B1 (ru)
CA (1) CA2842177C (ru)
CR (1) CR20140053A (ru)
EA (1) EA029305B1 (ru)
IL (1) IL230547A (ru)
IN (1) IN2014CN02188A (ru)
MX (1) MX350390B (ru)
MY (1) MY184277A (ru)
NZ (1) NZ620040A (ru)
PH (1) PH12016501175A1 (ru)
SG (1) SG2014013205A (ru)
UA (1) UA113522C2 (ru)
WO (1) WO2013028177A1 (ru)
ZA (1) ZA201401027B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP2018532806A (ja) * 2015-11-04 2018-11-08 キセラ バイオファーマシューティカルズ インコーポレイテッド デオキシコール酸およびその塩による蓄積脂肪の処置方法
KR101841193B1 (ko) * 2016-09-22 2018-03-22 이경락 저장성 지방 분해 조성물 및 그의 제조 방법
US20180078621A1 (en) * 2016-09-22 2018-03-22 Kyoung Lack Lee Composition for hypotonic lipolysis and manufacturing method thereof
US20190314388A1 (en) * 2018-04-16 2019-10-17 Penmix Ltd. Pharmaceutical composition containing deoxycholic acid
KR102172439B1 (ko) * 2018-12-05 2020-10-30 송미희 지방 분해용 조성물 및 이를 포함하는 주사제 조성물
KR102064864B1 (ko) 2019-02-08 2020-01-10 (주)제테마 국소 주사용 조성물
KR102111346B1 (ko) 2019-08-20 2020-05-22 아영창 침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물
KR20220026068A (ko) 2020-08-25 2022-03-04 강명범 지방 분해용 주사제 조성물
CN116617160A (zh) * 2023-07-25 2023-08-22 山东则正医药技术有限公司 水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
RU2224523C2 (ru) * 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6417179B1 (en) 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
EP2422789B1 (en) 2004-05-19 2017-11-22 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Injectable coposition comprising sodium deoxycholate
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
EP1888101B1 (en) 2005-06-06 2012-03-21 Georgetown University Compositions and methods for lipo modeling
TW201011755A (en) 2008-09-10 2010-03-16 Skymedi Corp Flash memory system and its data recovery method
JP5420946B2 (ja) * 2009-03-23 2014-02-19 富士フイルム株式会社 胆汁酸を含むミノキシジル水性組成物
EP2645099A1 (en) 2012-03-30 2013-10-02 Phares Pharmaceutical Research N.V. Biorelevant compositions

Also Published As

Publication number Publication date
SG2014013205A (en) 2014-05-29
KR102034606B1 (ko) 2019-10-22
AU2018202807B2 (en) 2020-01-16
EA029305B1 (ru) 2018-03-30
AU2011375432B2 (en) 2016-02-04
CN108619089A (zh) 2018-10-09
KR101919269B1 (ko) 2018-11-15
KR20170075016A (ko) 2017-06-30
KR20190119677A (ko) 2019-10-22
CN103826608A (zh) 2014-05-28
CR20140053A (es) 2014-06-12
IN2014CN02188A (ru) 2015-05-29
KR20200013103A (ko) 2020-02-05
JP5919597B2 (ja) 2016-05-18
KR102073536B1 (ko) 2020-02-04
MX2014001495A (es) 2014-04-25
KR20150000448A (ko) 2015-01-02
MY184277A (en) 2021-03-30
CA2842177C (en) 2016-07-19
IL230547A0 (en) 2014-03-31
KR20180123734A (ko) 2018-11-19
AU2011375432A1 (en) 2014-02-06
CN108743522A (zh) 2018-11-06
AU2018202807A1 (en) 2018-05-10
JP2014524467A (ja) 2014-09-22
AU2016202661A1 (en) 2016-05-19
NZ620040A (en) 2016-06-24
ZA201401027B (en) 2017-09-27
PH12016501175B1 (en) 2017-12-11
CA2842177A1 (en) 2013-02-28
BR112014000547B1 (pt) 2021-11-09
BR112014000547A2 (pt) 2017-02-14
UA113522C2 (xx) 2017-02-10
WO2013028177A1 (en) 2013-02-28
AU2016202661B2 (en) 2018-02-22
IL230547A (en) 2017-02-28
PH12016501175A1 (en) 2017-12-11
MX350390B (es) 2017-09-06
KR101751585B1 (ko) 2017-06-27

Similar Documents

Publication Publication Date Title
EA201490175A1 (ru) Составы дезоксихолевой кислоты и ее солей
EA201400483A1 (ru) Составы собирателей и способы их применения
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201390934A1 (ru) Композиции и способы модулирования fxr
UA113981C2 (xx) Офтальмологічний розчин, що містить диквафасол
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
MY171414A (en) Compositions and methods for improving the compatibility of water soluble herbicide salts
BR112015013430A2 (pt) método de aprimoramento da compatibilidade de uma solução herbicida aquosa; solução herbicida aquosa com compatibilidade aprimorada; e composição herbicida secante
EA201490812A1 (ru) Раствор для перорального введения
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
BR112016027760A8 (pt) método de síntese de ph baixo de complexo de zinco-lisina
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
CY1115372T1 (el) Συνθεσεις δεσοξυχολικου οξεος και αλατα αυτου
EA201691825A1 (ru) Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта)
EA201890018A1 (ru) Композиция для придания формы волосам
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
MX2014005399A (es) Metodos para tratar gota en sub-poblaciones de pacientes.
BR102013022476B8 (pt) Solução aquosa herbicida, método para melhorar sua compatibilidade, e composição herbicida seca
EA201790055A2 (ru) Составы дезоксихолевой кислоты и ее солей
BR112014002712A2 (pt) método para tratamento da esquizofrenia
EA201792582A1 (ru) Композиция для придания формы волосам
EA201992511A1 (ru) Составы дезоксихолевой кислоты и ее солей
PH12018501046A1 (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента